iny-03-041

INY-03-041, a potent and highly selective PROTAC-based pan-AKT degrader, inhibits AKT1, AKT2, and AKT3 with IC50s of 2.0 nM, 6.8 nM, and 3.5 nM, respectively. This compound consists of the ATP-competitive AKT inhibitor GDC-0068 conjugated to Lenalidomide.

INY-03-041 trihydrochloride, a potent and highly selective PROTAC-based pan-AKT degrader, comprises Ipatasertib, an ATP-competitive AKT inhibitor, conjugated to Lenalidomide. It effectively inhibits AKT1, AKT2, and AKT3 with IC50 values of 2.0, 6.8, and 3.5 nM, respectively [1].

9-Decyn-1-ol is an alkyl ether-based PROTAC linker used in synthesizing PROTACs, acting as a conjugation agent to combine GDC-0068 and Lenalidomide to form INY-03-041. INY-03-041 is a potent and highly selective pan-Akt degrader that inhibits Akt1, Akt2, and Akt3 with IC50 values of 2.0 nM, 6.8 nM, and 3.5 nM, respectively[1].

Ipatasertib-NH2 (GDC-0068-NH2;RG7440-NH2) is a ligand for the target protein AKT used in PROTAC, binding to lenalidomide, a ligand of ubiquitin E3 ligase cereblon (CRBN), via a ten-hydrocarbon linker to form INY-03-041 for AKT degradation[1].

Lenalidomide-C9-aldehyde is a synthesized E3 ligase ligand-linker conjugate that incorporates the Lenalidomide based cereblon ligand and a linker. Lenalidomide-C9-aldehyde can be used in the synthesis of a series of PROTACs, such as INY-03-041. INY-03-041

Ipatasertib-NH2 dihydrochloride is a ligand for the target protein AKT in PROTAC [INY-03-041], comprising Ipatasertib-NH2, a ten-hydrocarbon linker, and the CRBN ligand Lenalidomide, which functions as an E3 ubiquitin ligase.